News & Updates

NovoNordisk announces positive results with oral semaglutide

NovoNordisk

 

Novonordisk the leading Danish company for producing anti diabetic drugs announces  positive results for phase II testing of the oral hypoglycemic semaglutide.

In the trails semaglutide appeared to be safe and well tolerated with nausea and vomiting diminished over time.

 

“We are very pleased with the results of this trial confirming the potential of semaglutide to treat type 2 diabetes, both as a once weekly subcutaneous injection and as a once daily tablet”
Said Mads Krogsgaard Thomsen
executive vice president and chief science
officer of Novo Nordisk
Full announcement HERE.

 

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x